Deciphera Pharmaceuticals (NASDAQ:DCPH) Cut to Market Perform at Leerink Partnrs

Deciphera Pharmaceuticals (NASDAQ:DCPH) was downgraded by equities research analysts at Leerink Partnrs from an “outperform” rating to a “market perform” rating in a research note issued on Monday, Zacks.com reports.

DCPH has been the topic of a number of other reports. Barclays raised Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $9.00 to $26.00 in a report on Tuesday. JMP Securities reiterated a “market perform” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday. JPMorgan Chase & Co. boosted their price objective on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th. Guggenheim reissued a “neutral” rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday. Finally, Stifel Nicolaus upped their price target on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $24.17.

Deciphera Pharmaceuticals Trading Down 0.0 %

Shares of NASDAQ:DCPH opened at $25.27 on Monday. The company has a 50 day moving average of $15.98 and a 200-day moving average of $14.55. The firm has a market cap of $2.08 billion, a P/E ratio of -11.03 and a beta of 0.39. Deciphera Pharmaceuticals has a twelve month low of $9.90 and a twelve month high of $25.40.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The firm had revenue of $48.30 million during the quarter, compared to the consensus estimate of $45.93 million. During the same period in the prior year, the firm posted ($0.60) earnings per share. The firm’s revenue for the quarter was up 32.9% compared to the same quarter last year. Equities research analysts forecast that Deciphera Pharmaceuticals will post -2.16 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Deerfield Management Company L.P. Series C lifted its holdings in shares of Deciphera Pharmaceuticals by 2.8% during the third quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock worth $87,738,000 after buying an additional 190,580 shares during the last quarter. Deutsche Bank AG grew its position in Deciphera Pharmaceuticals by 36.7% during the third quarter. Deutsche Bank AG now owns 254,671 shares of the company’s stock worth $3,239,000 after buying an additional 68,435 shares in the last quarter. Panagora Asset Management Inc. acquired a new stake in Deciphera Pharmaceuticals during the third quarter worth about $1,167,000. Dark Forest Capital Management LP increased its stake in Deciphera Pharmaceuticals by 18.9% during the third quarter. Dark Forest Capital Management LP now owns 60,216 shares of the company’s stock valued at $766,000 after acquiring an additional 9,553 shares during the period. Finally, Diversified Trust Co acquired a new position in Deciphera Pharmaceuticals in the 4th quarter valued at approximately $193,000. 70.96% of the stock is owned by institutional investors.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.